K K Utne1, A Dahm2, H S Wik3, L P Jelsness-Jørgensen4, P M Sandset5, W Ghanima6. 1. Department of Internal Medicine, Østfold Hospital, Kalnes, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: kristin.kornelia.utne@so-hf.no. 2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Hematology, Akershus University Hospital, Lørenskog, Norway. 3. Department of Hematology, Oslo University Hospital, Oslo, Norway. 4. Department of Internal Medicine, Østfold Hospital, Kalnes, Norway; Department of Health Science, Østfold University College, Fredrikstad, Norway. 5. Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Hematology, Oslo University Hospital, Oslo, Norway. 6. Department of Internal Medicine, Østfold Hospital, Kalnes, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Abstract
INTRODUCTION: Despite treatment of acute deep vein thrombosis (DVT) with low molecular weight heparin and warfarin, up to 50% of patients develop post-thrombotic syndrome (PTS). Our aims were to assess whether treatment of DVT with rivaroxaban would reduce the rate of subsequent PTS and improve health-related quality of life (HRQoL) as compared to conventional anticoagulation with low molecular weight heparin (LMWH)/warfarin. MATERIALS AND METHODS: Consecutive patients with an objectively confirmed DVT diagnosed between 2011 and 2014 and treated with either rivaroxaban or warfarin were included in this study 24 (±6) months after DVT. PTS was assessed using the Patient Reported Villalta scale. HRQoL was assessed using the EQ-5D-3L and VEINES-QOL/Sym questionnaires. RESULTS: Total 309 patients were included, 161 (52%) treated with rivaroxaban and 148 (48%) with warfarin. Rivaroxaban-treated patients had a lower rate of PTS (45%: 95% confidence interval [CI] 37 to 52) compared to those treated with warfarin (59%: 95% CI 51 to 66, absolute risk difference 14%: 95% CI 3 to 25, odds ratio (OR) 0.6, P = .01). The adjusted OR for development of PTS was 0.5 (95% CI: 0.3 to 0.8, P = .01) in patients treated with rivaroxaban. HRQoL was significantly better in the rivaroxaban-treated patients. HRQoL measured by EQ-VAS (P = .002) and VEINES-QOL/Sym (P = .005/P = .003) remained significantly better after adjustment. CONCLUSIONS: Patients treated with rivaroxaban had lower rate of PTS and better HRQoL after DVT compared to patients treated with warfarin. However, these results should be interpreted with caution due to the limitation imposed by study design.
INTRODUCTION: Despite treatment of acute deep vein thrombosis (DVT) with low molecular weight heparin and warfarin, up to 50% of patients develop post-thrombotic syndrome (PTS). Our aims were to assess whether treatment of DVT with rivaroxaban would reduce the rate of subsequent PTS and improve health-related quality of life (HRQoL) as compared to conventional anticoagulation with low molecular weight heparin (LMWH)/warfarin. MATERIALS AND METHODS: Consecutive patients with an objectively confirmed DVT diagnosed between 2011 and 2014 and treated with either rivaroxaban or warfarin were included in this study 24 (±6) months after DVT. PTS was assessed using the Patient Reported Villalta scale. HRQoL was assessed using the EQ-5D-3L and VEINES-QOL/Sym questionnaires. RESULTS: Total 309 patients were included, 161 (52%) treated with rivaroxaban and 148 (48%) with warfarin. Rivaroxaban-treated patients had a lower rate of PTS (45%: 95% confidence interval [CI] 37 to 52) compared to those treated with warfarin (59%: 95% CI 51 to 66, absolute risk difference 14%: 95% CI 3 to 25, odds ratio (OR) 0.6, P = .01). The adjusted OR for development of PTS was 0.5 (95% CI: 0.3 to 0.8, P = .01) in patients treated with rivaroxaban. HRQoL was significantly better in the rivaroxaban-treated patients. HRQoL measured by EQ-VAS (P = .002) and VEINES-QOL/Sym (P = .005/P = .003) remained significantly better after adjustment. CONCLUSIONS:Patients treated with rivaroxaban had lower rate of PTS and better HRQoL after DVT compared to patients treated with warfarin. However, these results should be interpreted with caution due to the limitation imposed by study design.
Authors: Damon E Houghton; Alexander Lekah; Thanila A Macedo; David Hodge; Rayya A Saadiq; Yvonne Little; Ana I Casanegra; Robert D McBane; Waldemar E Wysokinski Journal: J Thromb Thrombolysis Date: 2020-02 Impact factor: 2.300
Authors: Ingrid M Bistervels; Roisin Bavalia; Jan Beyer-Westendorf; Arina J Ten Cate-Hoek; Sebastian M Schellong; Michael J Kovacs; Nicolas Falvo; Karina Meijer; Dominique Stephan; Wim G Boersma; Marije Ten Wolde; Francis Couturaud; Peter Verhamme; Dominique Brisot; Susan R Kahn; Waleed Ghanima; Karine Montaclair; Amanda Hugman; Patrick Carroll; Gilles Pernod; Olivier Sanchez; Emile Ferrari; Pierre-Marie Roy; Marie-Antoinette Sevestre-Pietri; Simone Birocchi; Hilde S Wik; Barbara A Hutten; Michiel Coppens; Christiane Naue; Michael A Grosso; Minggao Shi; Yong Lin; Isabelle Quéré; Saskia Middeldorp Journal: Res Pract Thromb Haemost Date: 2022-07-01
Authors: Pascale Notten; Jorinde H H van Laanen; Pieter Eijgenraam; Mark A F de Wolf; Ralph L M Kurstjens; Hugo Ten Cate; Arina J Ten Cate-Hoek Journal: Res Pract Thromb Haemost Date: 2020-04-08